Author： Moreno-Aspitia Alvaro Perez Edith A
Publisher： Future Medicine
ISSN： 1479-6694
Source： Future Oncology, Vol.1, Iss.6, 2005-12, pp. : 755-762
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Breast cancer remains the most common malignancy in women of developed countries. Taxanes are cornerstones in the treatment of breast cancer. Nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane™) is a novel taxane that obviates the need of using a toxic solvent such as Cremophor EL leading to a safer administration without standard premedication. Several factors such as the presence of albumin receptors in cell surface, the increased need of nutrients such as albumin by tumor cells and the lack of sequestering Cremophor micelles lead to increased intratumoral concentration of this new taxane. Recent trials have shown that ABI-007 is not only well tolerated but, compared with conventional paclitaxel, is associated with superior response rate, longer time to tumor progression and prolonged survival as second-line therapy in patients with metastatic breast cancer.
Related content
Access to resources
Recommend
By Altundag Kadri Bulut Nilufer Dizdar Omer Harputluoglu Hakan
Breast Cancer Research and Treatment, Vol. 100, Iss. 3, 2006-12 ,pp. :
By Yardley Denise Burris Howard Peacock Nancy Raefsky Eric Melnik Marianne Inhorn Roger Shipley Dianna Hainsworth John
Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. :